Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL – a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia A– at EAHAD 2019
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, has today announced results from its phase IIIb/IV clinical trial for ADYNOVATE at the 12th Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD), taking place 6-9 February, in Prague, Czech Republic. The PROPEL study is a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough Levels in subjects with severe hemophilia A.
The study showed that ADYNOVATE prophylaxis targeting 8–12% (HIGH) vs 1–3 % (LOW) trough levels was associated with a trend toward a higher proportion of patients with a total annualized all bleed rate (ABR)=0 (66% HIGH vs 39% LOW; p=0.075). The HIGH group was also associated with a trend toward a lower total ABR, as well as a higher proportion of patients with all annualized joint bleed rate (AJBR)=0 (90% HIGH vs 68% LOW) and all spontaneous ABR=0 (84% HIGH vs 61% LOW). The data suggests that optimizing FVIII profiles through PK-driven dosing that targets trough levels 8-12% was consistently achievable and further treatment personalization for patients with hemophilia A should be considered. Safety profiles were comparable and consistent with previous ADYNOVATE trials. Ongoing analyses will characterize the relationship between PK-tailored dosing of ADYNOVATE FVIII levels and bleeding events.
“The study reiterates the importance of personalized prophylaxis for those living with hemophilia,” said Dr. med. Robert Klamroth, Head of the Department of Internal Medicine Angiology and Coagulation Disorders and Director of the Comprehensive Care Haemophilia Treatment Center and the Haemostasis and Thrombosis Unit at the Vivantes Klinikum in Berlin, Germany. “The findings suggest the need to measure actual FVIII levels and show a clear trend that if we’re able to keep FVIII levels in a higher range, there may be better patient outcomes, including enhanced bleed protection that could help more patients reach zero bleeds.”
“At Takeda, we are proud of the hematology heritage Shire and Baxalta built over 60 years and we plan on expanding on it through continued research and innovation, including continued focus on direct factor replacement,” said Dr. med. Wolfhard Erdlenbruch, Vice President Head of Global Medical Affairs Hematology, Takeda. “We are excited to be at EAHAD and share the results of PROPEL study. The zero all bleed rates and zero all spontaneous joint bleeds in this study have not been reported previously with people living with hemophilia A. This supports that factor levels matter and brings us a step closer to achieving our goal of optimized and personalized patient care, because every bleed matters.”
In addition to PROPEL, Takeda will present a dozen scientific data releases on the company’s recently acquired broad portfolio of treatments for bleeding disorders throughout EAHAD, including:
- AHEAD international and German studies: Effectiveness, safety, and quality of life outcomes in hemophilia A patients treated with antihemophilic factor (recombinant) in a real world setting over 5 years.
- Insights into the evolution of haemophiliac arthropathy: The Irish personalised approach to the treatment of haemophilia (iPATH) study.
- Physical activity and haemophilic joint arthropathy amongst adults with severe haemophilia in Ireland: The Irish personalised approach to the treatment of haemophilia (iPATH) study.
- Barriers to physical activity amongst adults with moderate and severe haemophilia in Ireland: The Irish personalised approach to the treatment of haemophilia (iPATH) study.
- Results from a phase 3B, open-label, multicenter, continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Analysis by age group.
- Design of a phase 3, prospective, multicenter, open-label study of safety and hemostatic efficacy of rurioctocog alfa pegol in previously untreated patients <6 years of age with severe hemophilia A.
- Demographic and baseline data from patients with hemophilia and inhibitors enrolled in the FEIBA global outcomes (“FEIBA GO”) study.
- Analysis of joint bleeding events from a phase 3, multicenter, open-label study of on-demand recombinant von Willebrand factor (VWF) treatment in patients with severe von Willebrand disease (VWD).
- Evaluation of laboratory safety data from patients with severe von Willebrand disease (VWD) in association with infusion of recombinant von Willebrand factor (VWF) in a phase 3, multicenter, open-label study.
- Efficacy and safety of prophylaxis with recombinant von Willebrand factor (VWF) in severe von Willebrand disease (VWD): Design of a prospective, phase 3, open-label, international multicenter study.
- Nonclinical safety evaluation of a next generation factor IX (FIX) gene therapy construct (SHP648) in mice.
About the PROPEL Study
The PROPEL study evaluated the safety and efficacy of ADYNOVATE in PK-guided prophylaxis targeting two different FVIII trough levels in previously treated patients.
Methods: Eligible subjects had FVIII activity <1%, annualized bleed rate (ABR) ≥2, and transitioned from a previous SHP660 (ADYNOVATE) study or were 12–65 years old with ≥150 exposure days to plasma-derived or recombinant FVIII. After initial PK assessments, subjects received 12 months of PK-guided prophylaxis targeting FVIII trough levels of 1–3% (LOW) or 8–12% (HIGH) (1st 6 months: dose adjustment period). Primary outcome was the % of subjects with a total ABR=0 (all bleeds) during the 2nd 6-month study period. Secondary outcomes included total ABR, spontaneous ABR and joint ABR (AJBR) (all bleeds), and adverse events (AEs).
Results: Overall, 115 male subjects (57 LOW, 58 HIGH) received ≥1 SHP660 dose. Median (range) age was 28 (12–61) years; 106 subjects (56 LOW, 50 HIGH) completed the study. During the 2nd 6 months, total ABR=0 was achieved by 22/57 (39%) LOW, 38/58 (66%; P=0.075) HIGH, spontaneous ABR=0 by 35/57 (61%) and 49/58 (84%; P=0.141), respectively, and AJBR=0 by 39/57 (68%) and 52/58 (90%; P=0.179). Mean (SD), median (IQR) total ABRs for the 2nd 6-month period: 3.6 (7.3), 2.0 (4.0) LOW; 1.6 (3.3), 0 (2.0) HIGH. Overall AEs and SAEs occurred in 63% and 9% of subjects, with 1 HIGH subject (0.9%) SAE considered related to SHP660: a transient 0.6 BU inhibitor without evidence of anti-FVIII binding, which resolved by study end. AE profiles were comparable and consistent with previous SHP660 trials.
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] was first approved by the Food and Drug Administration (FDA) in the U.S. followed by approval in Japan, Canada, and Colombia, and is approved as ADYNOVI® in the 28 Member States of the European Union (EU) as well as Iceland, Liechtenstein, Norway and Switzerland. In Europe ADYNOVI is approved for the treatment and prophylaxis of bleeding in patients 12 years and above with hemophilia A.
ADYNOVI SAFETY INFORMATION FOR EUROPE
Please consult the ADYNOVI Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to dosing and treatment monitoring.
Hypersensitivity to the active substance, to the parent molecule octocog alfa or to any of the excipients listed in the SmPC. Known allergic reaction to mouse or hamster protein.
Special warnings and precautions for use
The medicinal product contains traces of mouse and hamster proteins. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.
The formation of neutralising antibodies (inhibitors) against factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay.
In general, all patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests. If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed.
After reconstitution this medicinal product contains 0.45 mmol sodium (10 mg) per vial.
|Common (Greater-than or equal to 1/100 to <1/10)||Headache, Diarrhea, Nausea, Rash|
|Uncommon (Greater-than or equal to 1/1000 to <1/100)||Factor VIII inhibition in previously-treated patients (PTPs), Hypersensitivity, Flushing|
For more information, please refer to the ADYNOVI Summary of Product Characteristics here.
About Takeda Hematology
Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real world experience.
We have 60+ years driving innovation for patients and a broad portfolio of 11 products across 9 hemophilia indications. Our experience as leaders in hematology means we are well prepared to meet today’s needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
+81 (0) 3-3278-2095
Media outside Japan
+1 (617) 551-2933
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ABB Wins $42 Million Order for Train Technologies from Indian Railways19.2.2019 08:30:00 | Pressemelding
ABB has won its largest traction equipment order in India, worth more than $42 million to supply state-of-the-art converters for electric locomotives from Diesel Locomotive Works (DLW), in Varanasi. The converters are custom designed for Indian Railways and will be manufactured at one of ABB’s largest factories for locomotive applications in Nelamangala, near Bengaluru, in Southern India. ABB’s traction solution is based on the latest technology to bring more reliable trains to passengers, while increasing sustainable transport use by moving from diesel trains to electric. This helps rail operators to achieve significant operational improvements. “We are delighted to be contributing to the electrification of India’s rail network with ABB’s locally manufactured solutions,” said ABB CEO Ulrich Spiesshofer. “By adopting advanced technologies, India is achieving rapid improvements in growth and productivity and shaping its economy for the era of digitalization.” “We are privileged to work
Exclusive Group Further Advances Global VAD Reach with Acquisition of SecureWave in Israel19.2.2019 08:06:00 | Pressemelding
Exclusive Group, the value-added services and technologies (VAST) group, today announced it is acquiring SecureWave, one of Israel’s leading independent cybersecurity VADs. The move adds another advanced economy to the worldwide market penetration of the Exclusive Group, establishes an in-country presence within one of the world’s most significant innovation hubs, and expands the Group’s service reach to the benefit of its global customers and partners. “This acquisition is about more than just filling in the gaps of our EMEA footprint – it represents a fantastic opportunity to tap into a significant new local market and use our in-country presence to extend relationships with Israeli-based technology innovators,” said Olivier Breittmayer, CEO at Exclusive Group. “In SecureWave we feel we have identified a like-minded VAD business with a committed and successful team who understand value. And as well as similar business principles, we also share some of the same cybersecurity and cloud
The O-RAN Alliance Announces New Open Fronthaul Specification, Demos and Industry Event at Mobile World Congress 201919.2.2019 08:00:00 | Pressemelding
The O-RAN Alliance announced today that it will be releasing the first O-RAN standard Open Fronthaul Specifications comprised of control, user, synchronization and management plane protocols. Sachin Katti, Stanford University Professor and O-RAN TSC co-chair said, “we are excited to release the first O-RAN Open Fronthaul Specification. O-RAN has leveraged significant specification work done in xRAN and will accelerate interoperability testing and product commercialization. Further, the O-RAN fronthaul workgroup has also started discussions on potential new study items to pursue for 2019.” An O-RAN industry event will kick off the MWC activities on Monday February 25th at 6:00pm, hosted by Deutsche Telekom on its stage in Hall 3. Following this event, O-RAN Alliance members will showcase six strategic proof-of-concepts across various member booths covering four key themes: intelligent RAN control, Open Interfaces, virtualization and white box. Chih-Lin I, China Mobile Chief Scientist an
Gain Therapeutics SA Announces Closing of EU 2.5 Million Series A Financing to Develop Novel Brain-Penetrant Non-Competitive Pharmacological Chaperones for Rare Lysosomal Storage Diseases and CNS Indications19.2.2019 07:30:00 | Pressemelding
GT Gain Therapeutics SA today announces that it has closed a €2.5 Million series A financing with VitaTech S.A. (€1.1Mio), Helsinn Investment Fund S.A. (€1Mio), and with existing investor TiVenture S.A. (€0.4). Gain Therapeutics SA is a private company, based in Lugano (Switzerland) and with a branch in Barcelona, that exclusively licensed an advanced computational technology (Site-directed Enzyme Enhancement Therapy, SEE-Tx®) used to identify next generation brain-penetrant non-competitive pharmacological chaperones. SEE-Tx® applicable to all diseases with a known genetic mutation in target proteins, allows the identification of brain-penetrant small molecules that provide a gain-of-function of misfolded proteins. Gain Therapeutics has already identified molecules for the treatment of a group of metabolic disorders called lysosomal storage disorders and some chronic degenerative diseases of the nervous system. Prof. Xavier Barril (CSO) commented: “The closing of this first part of ser
Australia Emerges as a Leading Innovator for Agriculture 4.019.2.2019 05:30:00 | Pressemelding
Australia’s long and distinguished history in agricultural research is cementing its position as a global hub for agriculture and food technology. Driven by a variety of climates and ecosystems, a stable and favourable business environment, and connectivity with the rapidly growing markets of Asia, Australia is capitalising on these advantages to become a centre for agtech and foodtech innovation. Australia for Agriculture 4.0, a new initiative by Austrade, the nation’s trade and investment promotion agency, will build on the country’s impressive record in agricultural innovation to facilitate foreign investment, exports and collaboration in both agtech and foodtech. The initiative aims to establish Australia as a global hub for agricultural and food innovation. It will showcase Australia’s agtech and foodtech capability, and highlight its unique technological advances, research excellence, strong record of innovation expertise, as well as the nation’s strong government support and est
Planview Empowers Organizations to Realize Agile-at-Scale with Lean and Agile Delivery Solution18.2.2019 15:05:00 | Pressemelding
Today’s increasingly competitive and disrupted markets require teams and enterprises to adapt quickly and speed delivery of innovative products, solutions, and customer experiences. While agile ways of working have produced positive results on single teams, leveraging Agile across the organization creates a challenge – how to scale delivery across teams for larger initiatives and focus on business outcomes for driving change and results. The Planview® solution for Lean and Agile delivery solves this challenge by connecting agile delivery with strategic planning and lean portfolio management to achieve business objectives faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190218005030/en/ The Planview solution for Lean and Agile delivery connects strategic planning, lean portfolio management, and work delivery. (Graphic: Business Wire) “When Planview came together with LeanKit® in December 2017, we significantly expanded